Alpha 0.1.0

Biotech411

Biotechnology. Right now.

All programs

Rare disease

Genglycos · glycogen storage disease Ia

Accelerated approval · As of

The DTX401 phase 3 study measured daily cornstarch use. FDA required further evidence of clinical benefit after accelerated approval.

Milestone history

  1. The phase 3 study DTX401-CL301 (NCT05139316) began.

    ClinicalTrials.gov
  2. The study reached its recorded completion date.

    ClinicalTrials.gov
  3. FDA granted accelerated approval as an adjunct to nutritional management for patients aged eight and older.

    FDA
  4. ClinicalTrials.gov posted the study’s first results tables.

    ClinicalTrials.gov